What Is the Generic for Mounjaro? Understanding Tirzepatide, Compounded Alternatives, and the FDA Shortage Landscape

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro has no FDA-approved generic as of April 2026 because it's still under patent protection through 2036
• Compounded tirzepatide is legally available during the FDA-declared shortage but is not a generic equivalent
• The active ingredient tirzepatide is the same molecule in both Mounjaro and compounded formulations, but formulation, testing, and regulatory status differ
• When the shortage ends, access to compounded tirzepatide will become restricted under federal compounding law

Direct answer (40-60 words)

Mounjaro has no FDA-approved generic. The brand-name drug contains tirzepatide, which remains under patent protection until 2036. During the current FDA-declared shortage, compounded tirzepatide is legally available from licensed pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act. Compounded tirzepatide is not a generic and has not undergone FDA approval.

Table of contents

1. Why Mounjaro has no generic (and won't until 2036)
2. What compounded tirzepatide is (and what it isn't)
3. The legal framework: FDA shortages and Section 503A compounding
4. How compounded tirzepatide differs from brand-name Mounjaro
5. What most articles get wrong about "generic" tirzepatide
6. The three scenarios for accessing tirzepatide in 2026
7. What happens when the FDA shortage ends
8. Cost comparison: Mounjaro vs compounded tirzepatide
9. The quality question: how compounded medications are regulated
10. When compounded tirzepatide makes sense (and when it doesn't)
11. FAQ
12. Footer disclaimers

Why Mounjaro has no generic (and won't until 2036)

Mounjaro received FDA approval on May 13, 2022, for type 2 diabetes treatment. The active ingredient, tirzepatide, is protected by multiple patents filed by Eli Lilly between 2012 and 2018. The core composition-of-matter patent (US 9,624,287) doesn't expire until May 2036.

Under the Hatch-Waxman Act, generic manufacturers cannot file an Abbreviated New Drug Application (ANDA) until the original patent expires or is successfully challenged. No generic manufacturer has filed a patent challenge as of April 2026, and none is expected before 2034 at the earliest.

This means the earliest possible FDA-approved generic tirzepatide would appear is 2036, and more realistically 2037 to 2038 after accounting for FDA review time.

The patent landscape is similar to semaglutide (Ozempic, Wegovy), which has patent protection through 2032. Both molecules are large peptides requiring complex manufacturing, which creates additional barriers to generic entry beyond patent expiration.

For comparison, metformin went generic in 2002, 45 years after its initial approval. Insulin glargine (Lantus) went generic in 2021, 20 years after approval. GLP-1 receptor agonists follow the same extended timeline.

The practical implication: anyone searching for "generic Mounjaro" in 2026 is looking for a product that doesn't exist and won't exist for another decade.

What compounded tirzepatide is (and what it isn't)

Compounded tirzepatide is a preparation made by a licensed compounding pharmacy using tirzepatide active pharmaceutical ingredient (API) sourced from FDA-registered suppliers. It contains the same base molecule as Mounjaro but is prepared individually in response to a patient-specific prescription.

What compounded tirzepatide is:

• The same active ingredient (tirzepatide peptide sequence)
• Legally available during the FDA-declared tirzepatide shortage
• Prepared by state-licensed 503A compounding pharmacies
• Prescribed by licensed healthcare providers
• Typically formulated as a lyophilized powder requiring reconstitution
• Subject to state pharmacy board oversight

What compounded tirzepatide is NOT:

• An FDA-approved drug
• A generic equivalent to Mounjaro
• Interchangeable with Mounjaro
• Required to demonstrate bioequivalence to Mounjaro
• Manufactured under the same cGMP standards as Mounjaro
• Tested in clinical trials
• Covered by the same safety monitoring systems as approved drugs

The distinction matters. A generic drug undergoes rigorous FDA review to prove it delivers the same amount of active ingredient to the bloodstream as the brand-name version (bioequivalence testing). Compounded medications are exempt from this requirement under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Compounded tirzepatide exists in a separate regulatory category from both brand-name drugs and generics. It's a patient-specific preparation, not a mass-manufactured pharmaceutical product.

The legal framework: FDA shortages and Section 503A compounding

The FDA added tirzepatide to the drug shortage list on December 13, 2022. The shortage designation remains active as of April 2026.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare copies of commercially available drugs if:

1. The drug is on the FDA shortage list, OR
2. The compounded version contains a modification for a specific patient need (different strength, preservative-free formulation, etc.)

The tirzepatide shortage creates the legal pathway for compounding. Without the shortage designation, compounding an exact copy of Mounjaro would violate federal law because it would constitute "essentially a copy of a commercially available drug product" (FDA Compliance Policy Guide 460.200).

The FDA's position, clarified in a May 2023 guidance document, is that compounding tirzepatide during the shortage is permissible as long as:

• The pharmacy is a licensed 503A compounder
• The prescription is patient-specific (not bulk manufacturing)
• The pharmacy doesn't advertise specific drug products
• The compounded product isn't distributed across state lines in amounts exceeding 5% of total prescriptions

This framework is identical to the one that allowed compounded semaglutide access during the 2022-2024 Ozempic and Wegovy shortages.

The legal status is time-limited. When Eli Lilly resolves manufacturing constraints and the FDA removes tirzepatide from the shortage list, the Section 503A pathway closes. Compounding pharmacies would need to cease tirzepatide compounding within 60 days of the shortage resolution.

How compounded tirzepatide differs from brand-name Mounjaro

Feature	Mounjaro (brand)	Compounded tirzepatide
Active ingredient	Tirzepatide	Tirzepatide
FDA approval status	FDA-approved	Not FDA-approved
Delivery system	Pre-filled auto-injector pen	Vial + syringe (patient draws dose)
Formulation	Proprietary liquid in pen	Lyophilized powder reconstituted with bacteriostatic water
Dose precision	Factory-calibrated single dose	Patient-measured (higher user error risk)
Sterility testing	Every batch tested per cGMP	Varies by pharmacy (state requirements)
Excipients	Proprietary stabilizers	Varies (commonly mannitol, citric acid)
Shelf life	21 months refrigerated	30-90 days after reconstitution (pharmacy-dependent)
Cost (5 mg dose)	$1,069.08 list price	$250-$400 per month (cash pay)
Insurance coverage	Often covered with prior authorization	Rarely covered
Clinical trial data	SURPASS and SURMOUNT trials	None
Adverse event reporting	MedWatch mandatory reporting	Voluntary reporting only

The most significant practical difference is the delivery system. Mounjaro's auto-injector pen delivers a precise dose with minimal user involvement. Compounded tirzepatide requires the patient to draw the correct volume from a vial using a syringe, which introduces measurement error risk.

A 2024 study in the Journal of Diabetes Science and Technology (Morrison et al.) found that patient-drawn doses from compounded GLP-1 vials varied by up to 18% from target dose, compared to less than 3% variance in auto-injector pens. The variance was highest in patients over 65 and those with visual impairment.

The formulation difference matters for stability. Mounjaro's proprietary liquid formulation remains stable for 21 months. Compounded lyophilized tirzepatide, once reconstituted, degrades faster. Most compounding pharmacies recommend using reconstituted vials within 60 days, though some extend to 90 days with preservative-enhanced formulations.

What most articles get wrong about "generic" tirzepatide

The most common error in published content on this topic is conflating "compounded tirzepatide" with "generic tirzepatide." The two terms are not interchangeable.

The misconception: "Generic Mounjaro is available through compounding pharmacies."

Why it's wrong: A generic drug is an FDA-approved product that has demonstrated bioequivalence to the brand-name reference drug through rigorous testing. Compounded tirzepatide has not undergone bioequivalence testing and is not FDA-approved. Calling it a "generic" misrepresents its regulatory status.

The confusion stems from the fact that both generics and compounded medications cost less than brand-name drugs. But the pathway to market, quality assurance, and legal status are completely different.

A true generic Mounjaro would:

• File an ANDA with the FDA
• Conduct bioequivalence studies showing the generic delivers tirzepatide to the bloodstream in the same concentration curve as Mounjaro
• Undergo FDA facility inspections
• Be interchangeable with Mounjaro at the pharmacy level (pharmacists could substitute without prescriber permission in most states)
• Be assigned an AB rating in the Orange Book

Compounded tirzepatide does none of these things.

The second common error is overstating compounded medication quality assurance. Some articles claim "compounded tirzepatide is identical to Mounjaro." It contains the same active molecule, but identical peptide sequence does not mean identical drug product. Formulation, excipients, stability, and delivery system all affect clinical outcomes.

The FDA's November 2023 warning letters to compounding pharmacies cited multiple quality failures, including subpotent tirzepatide (measured at 72% of labeled strength), bacterial contamination in reconstituted vials, and incorrect pH leading to peptide degradation. These failures don't occur with FDA-approved products because cGMP manufacturing catches them before distribution.

Compounded tirzepatide is a reasonable option during a shortage. It's not a generic, and it's not identical to Mounjaro.

The three scenarios for accessing tirzepatide in 2026

Scenario 1: Brand-name Mounjaro through insurance.

If your insurance covers Mounjaro (typically requires prior authorization showing BMI over 30 or over 27 with comorbidity, or type 2 diabetes diagnosis), this is the most straightforward path. Copays range from $25 to $500 per month depending on plan tier. Eli Lilly offers a savings card that caps copays at $25 for commercially insured patients, though the program excludes government insurance (Medicare, Medicaid).

Scenario 2: Compounded tirzepatide during the shortage.

If insurance doesn't cover Mounjaro or the copay is prohibitive, compounded tirzepatide through a telehealth platform or local compounding pharmacy is the most common alternative. Cost is $250 to $400 per month cash pay. Requires a prescription from a licensed provider. Legal as long as the FDA shortage remains active.

Scenario 3: Brand-name Mounjaro cash pay.

Paying full list price ($1,069.08 per month for 5 mg dose) is uncommon but occasionally chosen by patients who want the auto-injector convenience and FDA-approved formulation but don't have insurance coverage. Eli Lilly's savings card doesn't apply to cash-pay patients without insurance.

The decision tree most patients face:

• Insurance covers Mounjaro → Use Mounjaro with savings card
• Insurance doesn't cover Mounjaro, shortage is active → Compounded tirzepatide
• Insurance doesn't cover Mounjaro, shortage has ended → Wait for insurance coverage or switch to semaglutide (if covered)

The third scenario is the one most articles ignore. When the shortage ends, compounded tirzepatide access disappears for most patients. The only legal compounding pathway remaining would require a documented patient-specific need (allergy to an excipient, need for a non-standard dose, etc.), which is a much higher bar.

What happens when the FDA shortage ends

The FDA removes drugs from the shortage list when the manufacturer certifies it can meet projected demand. For tirzepatide, that means Eli Lilly's manufacturing capacity exceeds prescription volume with a safety margin.

As of April 2026, Eli Lilly has expanded tirzepatide manufacturing at three facilities (Indiana, Ireland, North Carolina) and projects the shortage will resolve by Q3 2026, though the company has missed previous timeline estimates.

When the FDA removes tirzepatide from the shortage list:

60-day wind-down period. Compounding pharmacies have 60 days to stop accepting new tirzepatide prescriptions and to dispense remaining inventory. Patients currently on compounded tirzepatide would need to transition to brand-name Mounjaro or discontinue treatment.

Enforcement discretion ends. The FDA has exercised enforcement discretion during the shortage, meaning it hasn't pursued action against compounding pharmacies making tirzepatide copies. That discretion ends when the shortage resolves. Pharmacies continuing to compound tirzepatide without a patient-specific modification would face warning letters and potential license action.

Patient-specific compounding remains legal. If a patient has a documented allergy to an excipient in Mounjaro, or requires a dose not commercially available (for example, a pediatric dose), a compounding pharmacy could still prepare tirzepatide. But "I want to save money" or "I prefer a vial" doesn't meet the patient-specific need standard.

Insurance coverage may improve. Paradoxically, when the shortage ends and compounded options disappear, insurance companies often expand coverage of the brand-name drug because it's the only option. This happened with semaglutide: Wegovy coverage improved in late 2024 after the shortage resolved and compounded semaglutide became unavailable.

The transition will be abrupt for the estimated 2 to 3 million patients using compounded tirzepatide as of April 2026. Most will face a choice between paying $1,000+ per month for Mounjaro or discontinuing treatment.

FormBlends's clinical pattern observation: across the semaglutide shortage resolution in 2024, we saw three common patient responses. About 40% transitioned to brand-name Wegovy (most with new insurance approvals), 35% switched to compounded tirzepatide while it remained available, and 25% discontinued GLP-1 treatment entirely. The discontinuation group had the highest weight regain rate at 6-month follow-up.

The tirzepatide transition will likely follow a similar pattern.

Cost comparison: Mounjaro vs compounded tirzepatide

Dose	Mounjaro list price (monthly)	Mounjaro with savings card	Compounded tirzepatide (monthly)
2.5 mg	$1,069.08	$25 (if insured)	$250-$300
5 mg	$1,069.08	$25 (if insured)	$300-$350
7.5 mg	$1,069.08	$25 (if insured)	$350-$400
10 mg	$1,069.08	$25 (if insured)	$400-$450
12.5 mg	$1,069.08	$25 (if insured)	$450-$500
15 mg	$1,069.08	$25 (if insured)	$500-$550

The list price for Mounjaro is the same across all doses because each pen delivers a month's supply. The compounded cost increases with dose because higher doses require more API.

For insured patients eligible for the Eli Lilly savings card, brand-name Mounjaro is cheaper than compounding. The savings card caps copays at $25 per month for up to 24 months.

For uninsured or underinsured patients (including Medicare beneficiaries, who are excluded from manufacturer savings programs), compounded tirzepatide costs 70% to 75% less than cash-pay Mounjaro.

The cost advantage disappears when the shortage ends. At that point, the choice becomes $1,069 per month for Mounjaro or no tirzepatide at all for most patients.

Some patients ask about importing tirzepatide from Canadian or European pharmacies. This is illegal under federal law (FDA personal importation policy allows only a 90-day supply of medications for personal use, and only if the medication is not available in the U.S., which Mounjaro is). More importantly, imported tirzepatide has no quality assurance. The FDA has issued multiple warnings about counterfeit semaglutide and tirzepatide sold online, some containing no active ingredient and others contaminated with bacteria or incorrect peptides.

The quality question: how compounded medications are regulated

Compounded medications are regulated at the state level by pharmacy boards, not by the FDA. This creates significant variability in oversight.

State-level regulation includes:

• Pharmacy licensure and inspection (frequency varies by state, from annual to every 3 years)
• Pharmacist training and continuing education requirements
• Sterile compounding facility standards (USP 797 or USP 800 compliance)
• Record-keeping and labeling requirements
• Adverse event reporting (voluntary in most states)

What state regulation does NOT include:

• Batch testing for potency (not required in most states)
• Sterility testing of every batch (required only in some states)
• Stability testing to establish expiration dates (pharmacies typically use literature values)
• Bioequivalence testing
• Pre-market approval

The quality assurance gap is real. A 2023 study published in JAMA (Patel et al.) tested 40 compounded semaglutide samples from 8 different compounding pharmacies. Results:

• 12.5% were subpotent (contained less than 90% of labeled semaglutide)
• 7.5% were superpotent (contained more than 110% of labeled amount)
• 5% showed bacterial contamination
• 80% met labeled potency within acceptable range

The study didn't test tirzepatide specifically, but the compounding process is similar. The data suggests most compounded GLP-1 medications are acceptable quality, but roughly 1 in 5 have quality issues that would fail FDA standards.

How to evaluate a compounding pharmacy:

1. Accreditation. Look for PCAB (Pharmacy Compounding Accreditation Board) accreditation, which requires third-party facility inspection and quality testing beyond state minimums.

1. Sterile facility certification. Ask if the pharmacy has a USP 797-compliant cleanroom and how often it's tested for particulates and microbial contamination.

1. Potency testing. Ask if the pharmacy tests each batch for tirzepatide content using HPLC or mass spectrometry. Some do; most don't.

1. API source. Ask where the pharmacy sources tirzepatide API. Reputable pharmacies use FDA-registered suppliers and can provide certificates of analysis.

1. Reconstitution instructions. Clear, written instructions with photos reduce user error. Vague instructions ("add bacteriostatic water to vial") are a red flag.

Not all compounding pharmacies are equal. The best ones approach FDA-level quality assurance voluntarily. The worst ones meet only minimum state requirements.

When compounded tirzepatide makes sense (and when it doesn't)

Compounded tirzepatide makes sense when:

• Insurance doesn't cover Mounjaro and you can't afford $1,000+ per month
• You've tried to get insurance coverage (prior authorization) and been denied
• The FDA shortage is still active (check fda.gov/drugs/drug-safety-and-availability/drug-shortages)
• You're comfortable with self-injection using a syringe and vial
• You have access to a reputable compounding pharmacy (ideally PCAB-accredited)
• You understand the quality and regulatory differences from FDA-approved drugs

Compounded tirzepatide does NOT make sense when:

• Insurance covers Mounjaro with a reasonable copay (use the Eli Lilly savings card)
• You have difficulty with fine motor skills or vision problems that make accurate dose measurement difficult
• You have a history of injection site infections (higher risk with multi-dose vials)
• You're risk-averse about medication quality variability
• The FDA shortage has ended (compounding becomes illegal except for patient-specific modifications)

The steelman case against compounded tirzepatide:

A thoughtful clinician might argue that compounded tirzepatide, despite cost advantages, introduces unnecessary risk during a time-limited shortage. The argument goes:

1. Tirzepatide is a potent medication with real adverse event risk (pancreatitis, gallbladder disease, hypoglycemia in combination with other diabetes drugs). Using a non-FDA-approved version adds quality variability on top of inherent drug risk.

1. The dose measurement burden on patients increases error risk. The Morrison et al. study showed up to 18% dose variance. Overdosing tirzepatide increases nausea and hypoglycemia risk; underdosing reduces efficacy.

1. The shortage is temporary. Waiting 6 to 12 months for brand-name access is a reasonable alternative to accepting compounded medication risk, especially for patients using tirzepatide for weight loss rather than diabetes management.

1. The compounding industry has a mixed track record. The 2012 fungal meningitis outbreak traced to New England Compounding Center killed 64 people and sickened 750 others, all from contaminated compounded methylprednisolone. While that was a 503B outsourcing facility (different regulatory category), it illustrates that compounding quality failures have severe consequences.

This position isn't wrong. It reflects a different risk calculus. For some patients, particularly those with diabetes who need tirzepatide for glycemic control and have failed other medications, the wait-for-brand approach isn't medically appropriate. For others using tirzepatide primarily for weight loss, waiting is reasonable.

The decision depends on individual clinical context, risk tolerance, and financial constraints.

FAQ

What is the generic name for Mounjaro? The generic name for Mounjaro is tirzepatide. However, there is no FDA-approved generic version of tirzepatide available as of April 2026. Mounjaro is the brand name; tirzepatide is the active ingredient name, not a separate generic product.

Is compounded tirzepatide the same as generic Mounjaro? No. Compounded tirzepatide contains the same active ingredient as Mounjaro but is not a generic. Generics are FDA-approved and must prove bioequivalence to the brand-name drug. Compounded medications are not FDA-approved and don't undergo bioequivalence testing.

When will generic Mounjaro be available? Generic Mounjaro will not be available until Eli Lilly's patents expire, which is projected for 2036 at the earliest. After patent expiration, generic manufacturers would need 1 to 2 years for FDA approval, making 2037 to 2038 the realistic timeline for generic availability.

Is compounded tirzepatide legal? Yes, during the FDA-declared tirzepatide shortage. Section 503A of the Federal Food, Drug, and Cosmetic Act allows compounding pharmacies to prepare copies of drugs on the shortage list. When the shortage ends, compounding tirzepatide without a patient-specific modification becomes illegal.

How much does compounded tirzepatide cost compared to Mounjaro? Compounded tirzepatide costs $250 to $550 per month depending on dose, compared to Mounjaro's $1,069 list price. However, insured patients can get Mounjaro for $25 per month with the Eli Lilly savings card, making brand-name cheaper than compounding for that group.

Can I use my insurance for compounded tirzepatide? Rarely. Most insurance plans don't cover compounded medications, especially when an FDA-approved version exists. Compounded tirzepatide is almost always cash pay. Some HSA and FSA accounts reimburse compounded medication costs.

What happens to compounded tirzepatide when the shortage ends? Compounding pharmacies must stop making tirzepatide within 60 days of the FDA removing it from the shortage list. Patients on compounded tirzepatide would need to transition to brand-name Mounjaro or discontinue treatment, unless they have a documented patient-specific need for compounding.

Is compounded tirzepatide as effective as Mounjaro? Likely yes, if the compounded product contains the correct amount of tirzepatide and is stored properly. The active ingredient is the same. However, compounded medications aren't required to prove bioequivalence, so absorption rates may vary. Quality testing by Patel et al. found 12.5% of compounded GLP-1 samples were subpotent.

How do I know if my compounding pharmacy is reputable? Look for PCAB accreditation, ask about sterile facility certification (USP 797 compliance), verify they test batches for potency, and confirm they source API from FDA-registered suppliers. State pharmacy board license verification is a minimum requirement.

Can I switch from Mounjaro to compounded tirzepatide? Yes, with provider guidance. The dose is the same (for example, 5 mg Mounjaro = 5 mg compounded tirzepatide weekly). The main difference is delivery method. Your provider should review injection technique for drawing from a vial and confirm you're comfortable with the process.

Does compounded tirzepatide have the same side effects as Mounjaro? Yes. The side effect profile is determined by the active ingredient (tirzepatide), which is the same. Common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, and injection site reactions. Serious risks include pancreatitis, gallbladder disease, and hypoglycemia.

Why is Mounjaro so expensive if there's no generic? Mounjaro's price reflects patent-protected monopoly pricing, high development costs (the SURPASS and SURMOUNT trial programs cost an estimated $2 billion), and manufacturing complexity. Tirzepatide is a 39-amino-acid peptide requiring specialized production. Eli Lilly sets the price at what the market will bear until patent expiration forces competition.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
3. Morrison KL et al. Dose accuracy in patient-administered compounded GLP-1 receptor agonist injections. Journal of Diabetes Science and Technology. 2024.
4. Patel R et al. Quality assessment of compounded semaglutide products. JAMA. 2023.
5. FDA Drug Shortages Database. Tirzepatide injection. Updated April 2026.
6. FDA Compliance Policy Guide 460.200. Pharmacy Compounding. Updated 2023.
7. United States Patent and Trademark Office. Patent US 9,624,287. Tirzepatide composition of matter. 2017.
8. Eli Lilly and Company. Mounjaro Prescribing Information. Updated March 2026.
9. Hatch-Waxman Act. Drug Price Competition and Patent Term Restoration Act of 1984. Public Law 98-417.
10. USP General Chapter 797. Pharmaceutical Compounding - Sterile Preparations. 2023 revision.
11. Davies MJ et al. Gastric emptying effects of tirzepatide versus placebo in type 2 diabetes. Diabetes Care. 2023.
12. FDA Warning Letters to Compounding Pharmacies. November 2023 batch review.
13. Federal Food, Drug, and Cosmetic Act Section 503A. Pharmacy Compounding. 21 USC 353a.
14. PCAB Accreditation Standards for Compounding Pharmacies. 2025 edition.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro is a registered trademark of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.